Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 6 (3) |
| Completed vs Stopped Early | 3 / 6 (40.0%) |
| Median Closed Actual Enrollment | 29 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Nationwide Children's Hospital | Columbus, OH | 6 |
| National Taiwan University Hospital | Taipei | 5 |
| Children's Hospital of The King's Daughters | Norfolk, VA | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05881408 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator | Phase III | ACTIVE NOT RECRUITING |
| NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | Phase III | TERMINATED |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sarepta Therapeutics across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Sarepta Therapeutics Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.